Redhill Biopharma (STU:2RH) Moat Score: 5/10 (As of Jul. 03, 2026)


STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma Moat Score?

Redhill Biopharma STU:2RH 18 Moat Score is 5 as of Jul. 03, 2026. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Redhill Biopharma ranks better than 94.67% on this metric.

Redhill Biopharma has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Redhill Biopharma has Narrow Moat: Redhill Biopharma Ltd has a solid narrow moat due to its portfolio of patents and ongoing R&D efforts in the pharmaceutical industry. While it has some pricing power and regulatory barriers, the competitive landscape limits its ability to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Redhill Biopharma might have Narrow Moat - Solid narrow moat.

Redhill Biopharma  (STU:2RH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Redhill Biopharma Moat Score Related Terms

STU:2RH vs SBFM, PRFX, CTTH: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Moat Score falls into.


STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Redhill Biopharma (STU:2RH) has a Moat Score of 5 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Redhill Biopharma ranks #55 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Redhill Biopharma's Moat Score too high?
Redhill Biopharma's current Moat Score is 5. Based on the distribution chart, Redhill Biopharma ranks #55 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's Moat Score compare to SBFM and PRFX?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #55 out of 1032 companies for Moat Score. This places Redhill Biopharma in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Redhill Biopharma's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current Moat Score of 5. The current Moat Score is 5. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current Moat Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price